Observational studyPloS one2025
A real-world pharmacovigilance analysis of acute renal failure associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe renal safety profile of sacubitril/valsartan remains debated in clinical practice. To address this uncertainty, we conducted a pharmacovigilance analysis of acute renal adverse events associated with sacubitril/valsartan using the FDA Adverse Event Reporting System (FAERS) database.
methodsUsing data from the FAERS database, we conducted an observational pharmacovigilance study from the first quarter (Q1) of 2015 to the fourth quarter of 2024 (Q4). The disproportionality analysis was performed using four algorithms: the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS).
resultsA total of 16,144,939 adverse events (AEs) were available on FAERS database, among these, 132,255 cases were associated with sacubitril/valsartan, 2,205 cases related to narrow acute renal failure (SMQs) and 3,232 cases with broad SMQs. And sacubitril/valsartan and acute renal adverse showed significant association both in narrow SMQs (ROR = 2.37; PRR = 2.34, χ2 = 1703.73; EBGM05 = 2.26) and the broad SMQs (ROR = 2.55, PRR = 2.51, χ2 = 2941.80, EBGM05 = 2.43). A total of 10 (19.23% of total) positive signals were obtained using the above four algorithms. Median age was 71 years, time to onset was within 30 days, and hospitalization rates of acute renal failure outcomes were 14.33% (narrow SMQs) and 30.69% (broad SMQs).
conclusionThe widespread use of sacubitril/valsartan has raised safety concerns, particularly regarding acute renal failure. Our study, leveraging real-world FAERS data, systematically analyzed this association, providing new evidence on acute renal failure risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.